A 22-year-old female patient with rare interlobar unicentric Castleman disease is presented. The tumour was discovered incidentally and thoracoscopic biopsy was planned to rule out malignancy. Due to dense adhesions to the adjacent anatomical structures and diffuse bleeding when mobilizing the tumour, a thoracoscopic approach was converted to thoracotomy. The tumour was removed without lung resection. Adjuvant radiotherapy was used to avoid possible recurrence of the disease. During the follow-up of 6 years, the patient remains free of any symptoms and evidence of recurrence.
Since publication of the National Lung Cancer Screening Trial (NLST) results early lung cancer detection has been widely studied, targeting individuals based on smoking history and age. However, over recent decades several changes in lung cancer epidemiology, including risk factors, have taken place. The aim of the current study was to explore smoking prevalence among lung cancer patients who had been treated surgically or undergone a diagnostic operation and whether these patients would have met the NLST inclusion criteria.All patients operated on for lung cancer in a university hospital in Estonia between 2009 and 2015 were included. Data were collected from hospital records.426 patients were operated on for lung cancer, with smoking history properly documented in 327 patients (87 females; median age 67 years). 170 (52%) patients were smokers, 97 (30%) patients were ex-smokers and 60 (18%) patients were nonsmokers. The proportion of females among smokers was 15%, among ex-smokers was 9% and among nonsmokers was 87%. 107 of our patients would not have met the NLST age criteria and 128 of our patients would not have met the NLST smoking criteria. In total, 183 patients (56% (79% of females and 48% of males)) would not have met the NLST inclusion criteria.Only half of surgically treated lung cancer patients were current smokers and more than half did not meet the NLST inclusion criteria.
Objective:Percutaneous tracheostomy is a common procedure but varies considerably in approach. The aim of our study was to evaluate the need for intraoperative bronchoscopy and to compare various surgical techniques.Methods:During 1 year all percutaneous tracheostomies in three intensive care units were prospectively documented according to a unified protocol. In one unit, bronchoscopy was used routinely and in others only during the study.Results:A total of 111 subjects (77 males) with median age 64 (range, 18–86) years and body mass index 25.4 (range, 15.9–50.7) were included. In unit A, tracheal wall was directly exposed; in unit B, limited dissection to enable tracheal palpation was made. In both units, bronchoscopy was used to check the location of an already inserted guiding needle; needle position required correction in 8% and 12% of cases, respectively. In unit C, in tracheostomies without pretracheal tissue dissection, bronchoscopy was used to guide needle insertion; needle position required correction in 66% of cases. Median duration of operations performed by thoracic surgeons and residents was 10 (range, 3–37) min and by intensive care doctors and residents was 16.5 (range, 3–63) min (p < 0.001). Time from the beginning of preparations for tracheostomy until the end of the whole procedure was median 32 min for bedside tracheostomies and 64 min for operations in the operating theatre (p < 0.001).Conclusion:Limited pretracheal tissue dissection enabled proper guiding needle insertion and bronchoscopy was rarely needed. Percutaneous tracheostomies performed by thoracic surgeons took less time, and duration of the whole procedure was remarkably shorter when performed at bedside.
Background: Previous recurrence risk models offered individualized prediction using a more diverse set of factors than traditional staging measures American Joint Committee on Cancer Tumor Node Metastasis (AJCC TNM) Staging System. Several studies have demonstrated gene mutation as a new prognostic factor, such as EGFR, KRAS and so on. This study aimed to analyze a comprehensive and reliable Nomogram prognostic model to predict recurrence in stage IA lung adenocarcinoma (ADC) with radical resection. Method: This was a retrospective, single-center and case-control study. Clinicopathologic, genetic, therapeutic features and survival status were collected. Univariate and multivariate Cox proportional hazards model was conducted. The nomogram for recurrence prediction was developed using Cox proportional hazards regression. Three nomograms were established based on a) AJCC 8 th TNM Staging, b) multivariate analysis results and c) risk factors recorded in published references. The higher concordance index (C-index) of model identified better performance of nomogram. Result: 1499 patients with pathological stage IA ADC from Cancer Hospital, Chinese Academy of Medical Sciences from October 2012 to December 2015 were enrolled in this study. The recurrence rate was 3.5% (53/1499). No recurrence of 180 patients randomly selected and analyzed in this study. Median DFS was not reached. The C-index of AJCC 8th TNM staging and the nomogram based on multivariate analysis was 0.598 (95% CI 0.538-0.659) and 0.696 (95% CI 0.629-0.764), respectively. The nomogram established on prognostic factors in previous studies, which included gene mutation such as EGFR, KRAS and ALK, showed higher discrimination with C-index 0.833 (95% CI 0.786-0.880). Conclusion: This was the first individualized nomogram combining clinicopathologic features with genetic information to predict recurrence in ADC. The nomogram added with gene mutation status demonstrated superior predictive capability comparing to other nomograms based on traditional AJCC T staging and multivariate analysis. Our nomogram was more reliable to guide prognostic factors and recurrence rate in stage IA ADC patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.